Menu

Alnylam Pharmaceuticals, Inc. (ALNY)

—
$460.06
+4.06 (0.89%)
Market Cap

$60.1B

P/E Ratio

N/A

Div Yield

0.00%

52W Range

$224.32 - $482.13

Company Profile

At a glance

• Alnylam is executing on its P5x25 strategy, transitioning to a top-tier, sustainably profitable biotech company driven by its differentiated RNAi platform and expanding commercial portfolio.

• The recent U.S. FDA approval of AMVUTTRA for ATTR amyloidosis with cardiomyopathy (ATTR-CM) marks a transformative milestone, significantly expanding the market opportunity for the flagship TTR franchise and accelerating revenue growth.

• Strong commercial performance in Q1 2025, with 28% total product revenue growth and 36% TTR franchise growth, underscores robust demand for existing products and provides a strong foundation for the ATTR-CM launch.

Price Chart

Loading chart...

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks